0001209191-21-026394.txt : 20210412
0001209191-21-026394.hdr.sgml : 20210412
20210412203355
ACCESSION NUMBER: 0001209191-21-026394
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20210408
FILED AS OF DATE: 20210412
DATE AS OF CHANGE: 20210412
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Loven Jakob
CENTRAL INDEX KEY: 0001753644
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39592
FILM NUMBER: 21821796
MAIL ADDRESS:
STREET 1: C/O ARVINAS, INC., 5 SCIENCE PARK
STREET 2: 395 WINCHESTER AVENUE
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kronos Bio, Inc.
CENTRAL INDEX KEY: 0001741830
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1300 S. EL CAMINO REAL
STREET 2: SUITE 300
CITY: SAN MATEO
STATE: CA
ZIP: 94402
BUSINESS PHONE: 212-871-7920
MAIL ADDRESS:
STREET 1: 1300 S. EL CAMINO REAL
STREET 2: SUITE 300
CITY: SAN MATEO
STATE: CA
ZIP: 94402
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-04-08
0
0001741830
Kronos Bio, Inc.
KRON
0001753644
Loven Jakob
C/O KRONOS BIO, INC.
1300 SO. EL CAMINO REAL, SUITE 300
SAN MATEO
CA
94402
1
0
0
0
Common Stock
2021-04-08
4
S
0
38312
27.09
D
1507032
I
See footnote
Common Stock
2021-04-08
4
S
0
24816
27.91
D
1482216
I
See footnote
Common Stock
2021-04-09
4
S
0
21660
27.20
D
1460556
I
See footnote
Common Stock
2021-04-12
4
S
0
15728
26.27
D
1444828
I
See footnote
Common Stock
2021-04-12
4
S
0
100
27.21
D
1444728
I
See footnote
Shares were sold pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.47 to $27.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The securities are held by Nextech V Oncology S.C.S, SICA-SIF ("Nextech V"). The Reporting Person currently serves as a member of the leadership team at Nextech Invest AG ("Nextech AG"), the investment advisor to Nextech V, and may be deemed to have shared voting and/or investment power over the securities held by Nextech V. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.47 to $28.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.82 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.01 to $27.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Darren DeStefano, Attorney-in-Fact
2021-04-12
EX-24.4_978896
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints
each of Catherine Rude and Darren DeStefano of Cooley LLP, signing individually,
the undersigned's true and lawful attorney-in-fact and agent to:
(1) Prepare and execute and file, for and on behalf of the undersigned, any and
all documents and filings that are required or advisable to be made with the
United States Securities and Exchange Commission, any stock exchange or similar
authority, under the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), and the rules and regulations promulgated thereunder, including without
limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange
Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or
any successor schedules or forms adopted under the Exchange Act) and any
amendments thereto in accordance with Section 13 of the Exchange Act and the
rules thereunder relating to securities of any company in which any entity
associated with the undersigned beneficially owns, or has at any time
beneficially owned, any equity interest (a "Portfolio Company"), and (b) Forms
3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the
Exchange Act and the rules thereunder relating to any Portfolio Company; and
(2) Take any other action of any nature whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in
the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to such attorneys-in-fact full power and authority
to do and perform any and every act and thing whatsoever requisite, necessary,
or proper to be done in the exercise of any of the rights and powers herein
granted, as fully to all intents and purposes as the undersigned might or could
do if personally present, with full power of substitution or revocation, hereby
ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this Power of Attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of undersigned, are not assuming, nor is
Cooley LLP assuming, any of the undersigned's responsibilities to comply with
the Exchange Act, including without limitation Sections 13 and 16 of the
Exchange Act.
This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file any form or
document with respect to the undersigned's holdings of and transactions in
securities issued by a company, (b) revocation by the undersigned in a signed
writing delivered to the foregoing attorney-in-fact, or (c) until such
attorney-in-fact shall no longer be associated with Cooley LLP (or its
successor), as applicable.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of the date written below:
Date: April 12, 2021 /s/ Jakob Loven